Sonendo, Inc. · OTC:SONX
Sonendo — Investor Presentation (January 2023)
24 slides from Sonendo's investor presentation, Jan 9, 2023
Slide 1: Sonendo Overview January 2023
Sonendo Overview January 2023
Slide 2: Disclaimer and Confidentiality Notice
Disclaimer and Confidentiality Notice This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cau
Slide 3: Our Mission: Saving Teeth. Improving Lives.
OUR MISSION Saving Teeth. Improving Lives. WHAT THIS MEANS Establish the GentleWave procedure as the standard of care for tooth decay, with an initial focus on transforming root canal therapy.
Slide 4: Introducing the Team
Introducing the Team Strong and Experienced Leadership Team Michael Watts Chief Financial Officer Michael Smith Chief Commercial Officer Andrew Kirkpatrick Chief Operating Officer Bjarne Bergheim President & CEO Roy Chen Chief Talent Officer
Slide 5: Key Success Factors for Sonendo
Paradigm-Shifting Platform Technology for Tooth Decay 1 Large Market Opportunity with Significant Need for Innovation 2 Compelling and Growing Body of Clinical and Real-World Evidence 3 Attractive Value Proposition for Dental Practitioners and Patients 4 Transformative R&D Capabilities and a Robust
Slide 6: Large Market for Root Canal Therapy (RCT)
Large Market for Root Canal Therapy (RCT) ~17M Root Canal Procedures Performed Annually in the U.S. and Canada Global prevalence of additional 30+ million procedures annually outside of the U.S. and Canada $1.9 Billion Endodontists (~5,000) Non-Referring General Practitioners (GPs) (~50,000) Remaini
Slide 7: The Root Canal System is Complex
Unique for each person, root and tooth Exhibit unpredictable three-dimensional curvature Include branches and connections between canals May bifurcate into multiple canals or converge into one canal The Root Canal System is Complex Root canals are complex… …making them difficult to effectively and e
Slide 8: Limitations in Clinical Outcomes and Clinical Workflow
Limitations in Clinical Outcomes Limitations in Clinical Workflow Ng YL. et al. Outcome of primary root canal treatment: systematic review of the literature -part 1. Effects of study characteristics on probability of success. Int Endod J. 2007; 40(12):921-39. POOR CLINICAL OUTCOMES, EXPERIENCES RCT
Slide 9: GentleWave System: Transforming RCT
First and only FDA-cleared system for RCT that employs a sterilized, single-use procedure instrument to automate the cleaning of root canals Superior cleaning and disinfection of microscopic spaces independent of root canal complexity and tooth structure Intuitive touchscreen interface simplifies pr
Slide 10: GentleWave System: Proprietary Mechanism of Action
Conventional Root Canal Therapy GentleWave Procedure Mechanism of Action Produces Tissue Dissolution Throughout the Root Canal System GentleWave System: Proprietary Mechanism of Action Degassing 1 Concentration Adjustments 2 Broad-Spectrum Acoustic Energy 3 Advanced Fluid Dynamics 4 Gen3 System
Slide 11: GentleWave System: Proprietary Mechanism of Action
GentleWave System: Proprietary Mechanism of Action
Slide 12: GentleWave Procedure Enables Superior Cleaning
Conventional RCT GentleWave Procedure VS GentleWave Procedure Enables Superior Cleaning
Slide 13: Clinical and Commercial Validation of the GentleWave Procedure
Clinical and Commercial Validation of the GentleWave Procedure Strong Clinical Outcomes & Superior Cleaning in a Less Invasive Procedure Enhanced Procedure Efficiency + In-Vivo and In-Vitro in… In Real-World, Clinical Practice with… 2 Prospective, Multi-Center Clinical Studies 30+ Peer-Reviewed Jour
Slide 14: Strong Clinical Outcomes
Strong Clinical Outcomes PURE Study: Single-Arm, Multi-Center, Prospective, Non-Significant Risk Clinical Study Note: Data for GentleWave and conventional RCT is from separate studies. Clinical data is not head-to-head. Ng YL. et al. Outcome of primary root canal treatment: systematic review of the
Slide 15: Enhanced Procedure Efficiency
Enhanced Procedure Efficiency Proven, Real-World Results Supported by Clinical Studies and Commercial Experience GentleWave Procedure Customer Survey1 Clinical Study Results Includes data from Sonendo’s GentleWave Procedure customer survey conducted in October 2020 (n=33) where users were polled abo
Slide 16: U.S. and Canada Commercial Strategy
U.S. and Canada Commercial Strategy Establishing the GentleWave Procedure as the Standard of Care for RCT Increase GentleWave Procedure Utilization Grow GentleWave Installed Base Drive Patients to GentleWave Providers How? Increase Referrals Targeted Direct-to-Patient Marketing Increase Awareness an
Slide 17: How We Structure Our Sales Team
How We Structure Our Sales Team KEY RESPONSIBILITIES Increase utilization in existing GentleWave practices Onboarding, clinical education and training Improve practice efficiency Drive patient referral volumes CONSUMABLE SALES REP Drive Account Utilization KEY RESPONSIBILITIES Win new business Estab
Slide 18: CleanFlow PI Our Next Generation Procedure Instrument
CleanFlow PI Our Next Generation Procedure Instrument TM CONFIDENTIAL
Slide 19: CleanFlow Procedure Instrument: Driving Procedure Simplicity
Molar PI CleanFlow PI CleanFlow Procedure Instrument: Driving Procedure Simplicity Cleans inside of tooth from outside Reduces procedure steps Easier and less technique-sensitive Confidence to use on more cases Fewer parts and easier to assemble Improved customer utilization Easier to teach procedur
Slide 20: GentleWave G4 System
DESIGNED FOR OPTIMIZED PERFORMANCE REFINED FOR A SIMPLIFIED WORKFLOW ENHANCED TO DELIVER AN ELEVATED EXPERIENCE Geared to support future software and evolving features Expanded Connectivity with both 2.4 and 5Ghz Wi-Fi compatibility Thermo-Electric Cooler enables system to operate over wider tempera
Slide 21: Our Key Growth Strategies
Our Key Growth Strategies Focused on Driving Long-Term, Sustainable Growth Strategy Execute U.S. and Canada Commercial Strategy Reduce Costs and Improve Production Efficiencies Invest in R&D Initiatives Expand into International Markets Key Elements Expand sales and marketing teams Grow installed ba
Slide 22: Financial Highlights
Financial Highlights Installed Base ~935 Consoles Placed Revenue Sales Territories 25 (Covering US and Canada) (3) As of September 30, 2022 2 $40.5M – $42.5M $33.2M $23.4M 3 (1) 2022 financial guidance issued on November 9, 2022 (2) Implied growth at the mid-point of guidance +25% +42% 3 1
Slide 23: Key Success Factors for Sonendo
Paradigm-Shifting Platform Technology for Tooth Decay 1 Large Market Opportunity with Significant Need for Innovation 2 Compelling and Growing Body of Clinical and Real-World Evidence 3 Attractive Value Proposition for Dental Practitioners and Patients 4 Transformative R&D Capabilities and a Robust
Slide 24: Thank You
(P Z SONENDO & THANK YOU /